Mentor Corporation (NYSE:MNT), a leading supplier of medical products for the global aesthetic market, announced that subject enrollment and initial dosing in its pivotal Phase IIIb study of its investigational botulinum toxin type A for the reduction of glabellar rhytides (frown lines) by intramuscular injection has been completed. Enrollment in the IIIb trial, which consisted of 700 subjects, began in late November and was completed in mid January. Joshua H. (Source: Cosmetic Medicine / Plastic Surgery News From Medical News Today)
More...
02-01-2008, 01:43 AM
Mentor announces completion of subject enrollment into phase iiib pivotal trial for b
Linear Mode
